drugset / Trial / NCT07545226
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
RandomizedParallel-groupOpen-labelBasic science
Summary
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of two evolocumab drug products in healthy participants.
Timeline
- Start
- 2026-04-21
- Primary completion
- 2026-09-03
- Completion
- 2026-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evolocumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.